Explore

Trendline Trendline
Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development
Trendline Trendline
Orano Appoints Frederic Desdouits as CEO of Orano Med to Drive Oncology Innovations

Orano Appoints Frederic Desdouits as CEO of Orano Med to Drive Oncology Innovations

Orano Appoints Frederic Desdouits as CEO of Orano Med to Drive Oncology Innovations
Trendline Trendline
Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage

Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage

Kelun-Biotech Gains Approval to Remove 'B' Marker, Signifying New Development Stage
Trendline Trendline
Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment

Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment

Sidewinder Therapeutics Secures $137 Million to Advance Cancer Treatment
Trendline Trendline
Cartography Biosciences and Gilead Sciences Collaborate on Novel Oncology Target for Cancer Therapies

Cartography Biosciences and Gilead Sciences Collaborate on Novel Oncology Target for Cancer Therapies

Cartography Biosciences and Gilead Sciences Collaborate on Novel Oncology Target for Cancer Therapies
Trendline Trendline
Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline

Gilead Acquires Tubulis for $5 Billion to Enhance Oncology Pipeline
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition

Gilead Sciences Expands Oncology Pipeline with Tubulis Acquisition
Reuters Reuters
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline

Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline

April 7 (Reuters) - Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, as the U.S. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs referred to as "guided missiles".
Trendline Trendline
Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline